McDaniel Mark A, Maier Steven F, Einstein Gilles O
Department of Psychology, University of New Mexico, Albuquerque, New Mexico 87131, USA.
Nutrition. 2003 Nov-Dec;19(11-12):957-75. doi: 10.1016/s0899-9007(03)00024-8.
We review the experimental evaluations of several widely marketed nonprescription compounds claimed to be memory enhancers and treatments for age-related memory decline. We generally limit our review to double-blind placebo-controlled studies. The compounds examined are phosphatidylserine (PS), phosphatidylcholine (PC), citicoline, piracetam, vinpocetine, acetyl-L-carnitine (ALC), and antioxidants (particularly vitamin E).
In animals, PS has been shown to attenuate many neuronal effects of aging, and to restore normal memory on a variety of tasks. Preliminary findings with humans, though, are limited. For older adults with probable Alzheimer's disease, a single study failed to demonstrate positive effects of PS on memory performance. For older adults with moderate cognitive impairment, PS has produced consistently modest increases in recall of word lists. Positive effects have not been as consistently reported for other memory tests. There is one report of consistent benefits across a number of memory tests for a subset of normal adults who performed more poorly than their peers at baseline. The choline compounds PC and citicoline are thought to promote synthesis and transmission of neurotransmitters important to memory. PC has not proven effective for improving memory in patients with probable Alzheimer's disease. The issue remains open for older adults without serious degenerative neural disease. Research on citicoline is practically nonexistent, but one study reported a robust improvement in story recall for a small sample of normally aging older adults who scored lower than their peers in baseline testing. Animal studies suggest that piracetam may improve neuronal efficiency, facilitate activity in neurotransmitter systems, and combat the age-related decrease in receptors on the neuronal membrane. However, for patients with probable Alzheimer's disease, as well as for adults with age-associated memory impairment, there is no clear-cut support for a mnemonic benefit of piracetam. Vinpocetine increases blood circulation and metabolism in the brain. Animal studies have shown that vinpocetine can reduce the loss of neurons due to decreased blood flow. In three studies of older adults with memory problems associated with poor brain circulation or dementia-related disease, vinpocetine produced significantly more improvement than a placebo in performance on global cognitive tests reflecting attention, concentration, and memory. Effects on episodic memory per se have been tested minimally, if at all. ALC participates in cellular energy production, a process especially important in neurons, and in removal of toxic accumulation of fatty acids. Animal studies show that ALC reverses the age-related decline in the number of neuron membrane receptors. Studies of patients with probable Alzheimer's disease have reported nominal advantages over a range of memory tests for ALC-treated patients relative to placebo groups. Significant differences have been reported rarely, however. Whether ALC would have mnemonic benefits for aging adults without brain disease is untested as far as we know. Antioxidants help neutralize tissue-damaging free radicals, which become more prevalent as organisms age. It is hypothesized that increasing antioxidant levels in the organism might retard or reverse the damaging effects of free radicals on neurons. Thus far, however, studies have found that vitamin E does not significantly slow down memory decline for Alzheimer's patients and does not produce significant memory benefits among early Parkinson's patients. Neither did a combination of vitamins E and C significantly improve college students' performance on several cognitive tasks.
In sum, for most of the "brain-specific" nutrients we review, some mildly suggestive effects have been found in preliminary controlled studies using standard psychometric memory assessments or more general tests designed to reveal cognitive impairment. We suggest that future evaluations of the possible memory benefits of these supplements might fruitfully focus on memory processes rather than on memory tests per se.
我们回顾了几种广泛销售的非处方化合物的实验评估,这些化合物据称具有增强记忆力的作用,并可用于治疗与年龄相关的记忆力衰退。我们的综述一般限于双盲安慰剂对照研究。所研究的化合物包括磷脂酰丝氨酸(PS)、磷脂酰胆碱(PC)、胞磷胆碱、吡拉西坦、长春西汀、乙酰左旋肉碱(ALC)以及抗氧化剂(特别是维生素E)。
在动物实验中,PS已被证明可减轻衰老对神经元的多种影响,并能在各种任务中恢复正常记忆。然而,在人体中的初步研究结果有限。对于可能患有阿尔茨海默病的老年人,一项研究未能证明PS对记忆表现有积极作用。对于有中度认知障碍的老年人,PS在单词列表回忆方面持续产生适度的提升。对于其他记忆测试,尚未一致报道有积极作用。有一份报告称,对于一部分在基线时表现比同龄人差的正常成年人,在多项记忆测试中都有持续的益处。胆碱化合物PC和胞磷胆碱被认为可促进对记忆重要的神经递质的合成和传递。PC尚未被证明对可能患有阿尔茨海默病的患者改善记忆有效。对于没有严重退行性神经疾病的老年人,这个问题仍未明确。关于胞磷胆碱的研究实际上不存在,但一项研究报告称,对于一小部分正常衰老且在基线测试中得分低于同龄人的老年人,在故事回忆方面有显著改善。动物研究表明,吡拉西坦可能提高神经元效率,促进神经递质系统的活性,并对抗神经元膜上与年龄相关的受体减少。然而,对于可能患有阿尔茨海默病的患者以及有年龄相关性记忆障碍的成年人,没有明确证据支持吡拉西坦对记忆有帮助。长春西汀可增加大脑的血液循环和新陈代谢。动物研究表明,长春西汀可减少因血流减少导致的神经元损失。在三项针对有与脑循环不良或痴呆相关疾病的记忆问题的老年人的研究中,长春西汀在反映注意力、专注力和记忆的整体认知测试中的表现比安慰剂有显著改善。对情景记忆本身的影响即使有测试也极少。ALC参与细胞能量产生,这一过程在神经元中尤为重要,并且参与清除脂肪酸的有毒积累。动物研究表明,ALC可逆转与年龄相关的神经元膜受体数量下降。对可能患有阿尔茨海默病的患者的研究报告称,与安慰剂组相比,接受ALC治疗的患者在一系列记忆测试中有一定优势。然而,很少有显著差异的报道。就我们所知,尚未测试ALC对没有脑部疾病的老年人是否有记忆益处。抗氧化剂有助于中和损害组织的自由基,随着生物体衰老,自由基会变得更加普遍。据推测,提高生物体中的抗氧化剂水平可能会延缓或逆转自由基对神经元的损害作用。然而,到目前为止,研究发现维生素E并不能显著减缓阿尔茨海默病患者的记忆衰退,也未在早期帕金森病患者中产生显著的记忆益处。维生素E和C的组合也未显著提高大学生在多项认知任务中的表现。
总之,对于我们综述的大多数“大脑特异性”营养素,在使用标准心理测量记忆评估或旨在揭示认知障碍的更一般测试的初步对照研究中发现了一些轻微的暗示性效果。我们建议,未来对这些补充剂可能的记忆益处的评估不妨富有成效地聚焦于记忆过程而非记忆测试本身。